Oregon Cancer Researcher to Present Findings in Europe

UbiVac CEO Dr. Bernard A. Fox will address London meeting on developing anti-cancer immunotherapeutic drugs

Contact: Patricia Pearson, [email protected], 503.887.1871

FOR IMMEDIATE RELEASE

Portland, Oregon—The European Medicines Agency (EMA) and the Cancer Drug Development Forum (CDDF) have selected Dr. Bernard A. Fox, PhD, president and chief executive officer, UbiVac, www.ubivac.com, to anchor a session at a major medical conference in London, England February 4-5, 2016.

Dr. Fox will provide his perspective on “Novel Biomarkers: Pitfalls, Limitations and Emerging Options.” His remarks will include insights gained during more than 10 years of research at Providence Portland Medical Center and as founder of UbiVac, a clinical stage immuno-oncology company. He will be joined by representatives of the USA, Canada and eight, Europe-focused institutions and companies.

According to the CDDF, this joint, multi-stakeholder meeting has been called as a result of the rapid growth of immunotherapy-based medicinal products in oncology that are bringing important advances in patient care and considerably changing treatment options, particularly in melanoma and lung cancers.

“I applaud the organizers for this timely initiative to help highlight some of the challenges we all face,” Dr. Fox said. “Developing new and better approaches that combine innovative therapies is a global undertaking. This is a good opportunity to assess the relative efficacy of each, identify those with the most promise, and bring them through regulatory processes as a top priority. I look forward to providing input.”

The two-day EMA-CDDF workshop (http://cddf.org/) in London will include academics, regulators and industry representatives.

About UbiVac

UbiVac is a clinical stage Immuno-Ongology company engaged in development of immunotherapies to combat cancer. UbiVac’s DPV-001 is currently in a Phase II randomized multi-center adjuvant study for non-small cell lung cancer. UbiVac has ongoing preclinical and discovery programs using DRibble, nanoparticles and spread-defective Cytomegalovirus (sdCMV). Founded in Portland, Ore. in 2005 by Drs. Bernard A. Fox and Hong Ming Hu, UbiVac is a spinout of the Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute at Providence Portland Medical Center. In 2011 UbiVac, in cooperation with Oregon Health & Science University (OHSU), created UbiVac CMV to license sdCMV.